Bio Plus Co

Bio Plus Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 66.39 M KRW. In the previous year, Stock-Based Compensation (SBC) was 188.39 M KRW — a change of -64.76% (lower).

Stock-Based Compensation

66.39 MKRW

YoY

-64.76%

Last updated:

Stock-Based Compensation (SBC) of Bio Plus Co is 2024 66.39 M KRW. Stock-Based Compensation (SBC) of Bio Plus Co was 2023 188.39 M KRW. It decreases by -64.76% lower compared to the previous year.

The Bio Plus Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
166.08 M KRW
Jan 1, 2020
151.38 M KRW
Jan 1, 2021
35.98 M KRW
Jan 1, 2022
450.00 M KRW
Jan 1, 2023
188.39 M KRW
Jan 1, 2024
66.39 M KRW
The Bio Plus Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
66.39 MKRW-64.76%
188.39 MKRW-58.14%
450.00 MKRW+1,150.54%
35.98 MKRW-76.23%
151.38 MKRW-8.85%
166.08 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Stock-Based Compensation (SBC) of Bio Plus Co is 66.39 M KRW in 2024.

Stock-Based Compensation (SBC) of Bio Plus Co changed from 188.39 M KRW to 66.39 M KRW, representing a -64.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co